Cargando…

Therapeutic Targets in Chronic Lymphocytic Leukemia

Detalles Bibliográficos
Autores principales:	Laurenti, Luca, Efremov, Dimitar G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694246/ https://www.ncbi.nlm.nih.gov/pubmed/33158264 http://dx.doi.org/10.3390/cancers12113259

Ejemplares similares

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab
por: Laurenti, Luca, et al.
Publicado: (2016)

The Use of Monoclonal Antibodies in the Treatment of Autoimmune Complications of Chronic Lymphocytic Leukemia
por: Laurenti, Luca, et al.
Publicado: (2013)

Clinical and molecular features of familial chronic lymphocytic leukemia: a pilot monocentric study
por: Benintende, Giulia, et al.
Publicado: (2022)

CD200 and Chronic Lymphocytic Leukemia: Biological and Clinical Relevance
por: D’Arena, Giovanni, et al.
Publicado: (2020)

Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL
por: Efremov, Dimitar G., et al.
Publicado: (2012)

Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance
por: Dal-Bo, Michele, et al.
Publicado: (2009)

Allogeneic Transplantation for Chronic Lymphocytic Leukemia
por: Laurenti, Luca, et al.
Publicado: (2010)

Chlorambucil plus Rituximab as Front-Line Therapy in Elderly/Unfit Patients Affected by B-Cell Chronic Lymphocytic Leukemia: Results of a Single-Centre Experience
por: Laurenti, Luca, et al.
Publicado: (2013)

Chronic Lymphocytic Leukemia
por: Vaisitti, Tiziana, et al.
Publicado: (2020)

CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia
por: D’Arena, Giovanni, et al.
Publicado: (2021)

Role of microRNAs in Chronic Lymphocytic Leukemia
por: Autore, Francesco, et al.
Publicado: (2023)

Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies
por: Efremov, Dimitar G., et al.
Publicado: (2020)

Chronic lymphocytic leukemia in China
por: Gale, Robert Peter
Publicado: (2022)

Targeting the A2A adenosine receptor counteracts immunosuppression in vivo in a mouse model of chronic lymphocytic leukemia
por: Arruga, Francesca, et al.
Publicado: (2020)

Measurable residual disease in chronic lymphocytic leukemia
por: Benintende, Giulia, et al.
Publicado: (2023)

Treatment Options for Elderly/Unfit Patients with Chronic Lymphocytic Leukemia in the Era of Targeted Drugs: A Comprehensive Review
por: Fresa, Alberto, et al.
Publicado: (2021)

IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia
por: Bulian, Pietro, et al.
Publicado: (2012)

The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells
por: Dal Bo, Michele, et al.
Publicado: (2015)

Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia: A Comprehensive Review
por: Autore, Francesco, et al.
Publicado: (2021)

Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia
por: Vitale, Candida, et al.
Publicado: (2023)

T cells in chronic lymphocytic leukemia: can they fight?
por: Vardi, Anna, et al.
Publicado: (2017)

The New Face of Autophagy in Chronic Lymphocytic Leukemia
por: Kopeina, Gelina S., et al.
Publicado: (2023)

Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review
por: Autore, Francesco, et al.
Publicado: (2018)

Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia
por: Shapiro, Mika, et al.
Publicado: (2017)

Therapeutic advancement of chronic lymphocytic leukemia
por: Lu, Kang, et al.
Publicado: (2012)

Targeting Mitochondrial Bioenergetics as a Therapeutic Strategy for Chronic Lymphocytic Leukemia
por: Roy Chowdhury, Subir, et al.
Publicado: (2018)

Pathogen‐specific B‐cell receptors drive chronic lymphocytic leukemia by light‐chain‐dependent cross‐reaction with autoantigens
por: Jiménez de Oya, Nereida, et al.
Publicado: (2017)

Rapid transitions in the standard of care for chronic lymphocytic leukemia (CLL)
por: Seymour, Erlene K.
Publicado: (2019)

TIGIT: an immune checkpoint beyond T cells in chronic lymphocytic leukemia
por: Seiffert, Martina
Publicado: (2023)

Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia
por: Wang, Jiguang, et al.
Publicado: (2014)

Recent therapeutic advances in chronic lymphocytic leukemia
por: Bose, Prithviraj, et al.
Publicado: (2017)

BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia
por: Smith, Lindsay D., et al.
Publicado: (2019)

Targeted treatment for chronic lymphocytic leukemia
por: Masood, Aisha, et al.
Publicado: (2011)

A step ahead toward precision medicine for chronic lymphocytic leukemia
por: Patriarca, Andrea, et al.
Publicado: (2020)

Boosting chemokine receptor recycling: an elixir of life for chronic lymphocytic leukemia
por: Patrussi, Laura, et al.
Publicado: (2018)

Multiple Distinct Sets of Stereotyped Antigen Receptors Indicate a Role for Antigen in Promoting Chronic Lymphocytic Leukemia
por: Messmer, Bradley T., et al.
Publicado: (2004)

Targeting the tumor microenvironment in chronic lymphocytic leukemia
por: Svanberg, Rebecka, et al.
Publicado: (2021)

Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12
por: Autore, Francesco, et al.
Publicado: (2019)

A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia
por: Ljungars, A., et al.
Publicado: (2018)

Neglected players: Tumor associated neutrophils involvement in chronic lymphocytic leukemia progression
por: Podaza, Enrique, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c5ni0vgjvo6kf0b8ep0n58frok